Overview

A Single Oral Dose, Crossover Comparative PK Study of WD-1603 in Healthy Subjects Under Fasting Conditions

Status:
Not yet recruiting
Trial end date:
2021-03-18
Target enrollment:
Participant gender:
Summary
An open label, balanced, randomized, two-treatment, two-period, two-sequence, single oral dose, crossover comparative Pharmacokinetics study of WD-1603 extended-release carbidopa/levodopa tablets in normal, healthy, adult human subjects under fasting conditions
Phase:
Phase 1
Details
Lead Sponsor:
Hong Kong WD Pharmaceutical Co., Limited